In another patient with paired pre- and post-treatment samples, two distinct subclones persisted post venetoclax-based treatment. Both had subclone-specific mechanisms to further resistance: a shift toward MEP-like cells and NF1 loss. Go and read more about the other cases! 📜 4/5
